BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China · Delayed Price · Currency is CNY

30.70

-1.35 (-4.21%)

Oct 22, 2026, 4:00 PM EDT

Market Cap	13.36B -39.5%
Revenue (ttm)	1.36B +17.4%
Net Income	96.27M -3.7%
EPS	0.23 -2.0%
Shares Out	435.23M
PE Ratio	132.38
Forward PE	n/a
Dividend	0.02 (0.05%)
Ex-Dividend Date	Jun 9, 2026

Volume	6,203,620
Open	32.03
Previous Close	32.05
Day's Range	30.70 - 32.39
52-Week Range	28.74 - 72.88
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, res... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 1,199

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688166

Full Company Profile

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 54.51 million, a decrease of -71.18%.

Financial Statements